GlassScriptPhysician profile
Annika M Abrahamson
NPI 1881693927
$5,826.70
in general payments reported to CMS, 2019-2025
44 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $173 · 2021: $684 · 2022: $542 · 2023: $759 · 2024: $902 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Entertainment: $35.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.29 |
| Entertainment | $35.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $970.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $835.20 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $671.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $401.16 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $354.16 | 2019-2025 | Repatha, Otezla, Tavneos |
| Lilly USA, LLC | $277.66 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $234.06 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $140.90 | 2019-2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $138.77 | 2021 | |
| Glaxosmithkline, LLC. | $138.24 | 2019-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $129.92 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $116.94 | 2023 | Veozah |
| Amarin Pharma, INC. | $110.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.53 | 2024-2025 | |
| Esperion Therapeutics, INC. | $90.10 | 2021-2025 | Nexletol |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.94 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $76.06 | 2025 | Rexulti |
| Allergan, INC. | $69.94 | 2019-2020 | |
| Genentech USA, INC. | $64.33 | 2019 | |
| Viatris Specialty LLC | $60.81 | 2025 | Yupelri |
| Exact Sciences Corporation | $59.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $57.67 | 2019 | |
| Philips North America LLC | $57.55 | 2024-2025 | (5050) Extended Holter, Extended Holter |
| Teva Pharmaceuticals USA, INC. | $57.54 | 2019-2024 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $51.54 | 2022 | |
| Boston Scientific Corporation | $49.95 | 2019-2024 | Watchman Flx |
| Radius Health, INC. | $49.39 | 2019 | |
| Biogen, INC. | $47.09 | 2025 | Skyclarys |
| Optos, INC. | $35.16 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch Health US, LLC | $32.79 | 2019 | |
| Sanofi Pasteur INC. | $30.05 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $29.42 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $29.22 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $29.19 | 2025 | Opsumit, Uptravi |
| Dexcom, INC. | $23.35 | 2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $20.28 | 2021 | |
| Lundbeck LLC | $18.24 | 2023 | Vyepti |
| Genzyme Corporation | $18.02 | 2023 | |
| Mylan Specialty L.P. | $14.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.87 | 2024 | Spravato |
| Irhythm Technologies, INC. | $12.32 | 2019 | |
| Eisai INC. | $12.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annika Abrahamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.